Ontario’s COVID-19 Genomics Rapid Response Coalition 

 

    About    

To accelerate the genomic characterization and surveillance of SARS-CoV-2 in Ontario and to help expedite patient genome sequencing through a coordinated approach bringing together all of the province’s genomics resources and capacity to enable timely and comprehensive genomic analysis.

Genomics

Infrastructure

Standardized Sequencing Methodologies

Bioinformatics

Infrastructure

Data Management & Sharing

The ON-CoV Coalition is designed to provide for method standardization and coordination of:

1

Collecting Patient Samples and Metadata

2

Sequencing

3

Data Curation and Management

4

Epidemiological Studies 

This work will expedite real-time testing and reporting to inform public health and public policy, help manage and overcome the ongoing COVID-19 crisis and ensure scalability for Ontario’s future pandemics preparedness.

Why Genomics?

Genomic technologies are the foundation for the solutions necessary to combat the ongoing COVID-19

pandemic. Ontario’s world-leading expertise in genomics, bioinformatics, genomics epidemiology, and artificial intelligence, can expedite Ontario’s response to COVID-19. 

The results reported by the Coalition will inform vaccine and therapeutic development.

Why Ontario Genomics?

Over the past 20 years, Ontario Genomics, together with the Ontario Government, Genome Canada, and academic, clinical and industry partners, has built a world-leading genomics ecosystem in Ontario with over $2.7B in funding leveraged for research, translation and the establishment of genomic technology platforms. 

Ontario Genomics is well-positioned to provide and promote:
COLLABORATION
LEADERSHIP
EXPERTISE
 

    Members    

ONCoV Genomics Coalition Members

Aaron Campigotto

University of Toronto

Bettina Hamelin

Ontario Genomics

Samira Mubareka

Sunnybrook Health Sciences / University of Toronto

Danielle Brabant-Kirwan

Health Sciences North

Robyn Lee

Dalla Lana School of Public Health, University of Toronto

Letitia Nadalin Penno

Canadore College

Nahuel Fittipaldi

Public Health Ontario

Andrew G. McArthur

McMaster University

Marc Fiume

DNAstack

Allison McGeer

Sinai Health Systems

Stephen Scherer

Hospital for Sick Children / University of Toronto

TCAG / CGEn

Prameet M. Sheth

Kingston Health Sciences Centre / Queen’s University

Jared Simpson

Ontario Institute for Cancer Research

Michael Szego

Unity Health Toronto / University of Toronto

David Villeneuve

Canadore College

Bo Wang

Peter Munk Cardiac Centre, UHN / University of Toronto

W-SWootton.jpg

Sarah Wootton

University of Guelph

 

We are proactively working with the research community, partner genome centres, and governments to accelerate the genomic characterization and surveillance of SARS-CoV-2 in Ontario. Learn more and stay up-to-date about our COVID-19 programs and important resources.

 

    Partners    

 

Canada’s BioRevolution 2020 Webinar Series – “Editing our Economic Future: The Power of CRISPR”

September 28, 2000 - 12pm

“Editing our Economic Future: The Power of CRISPR” will showcase a conversation between Gairdner Foundation laureates and leading Canadian researchers on using the opportunities and applications of gene editing, specifically by using CRISPR/Cas9, to transform multiple sectors.

September 15, 2020

Government of Canada: Policy Statement on Research Security and COVID-19

September 14, 2020

The Government of Canada is encouraging all members of the research ecosystem to be aware of the potential risks to their work and asking them to take appropriate measures to protect their knowledge creation and innovations, all while maintaining a strong commitment to Open Science and support for a global research response to the COVID-19 pandemic.

Predicting the recombination potential of severe acute respiratory syndrome coronavirus 2 and Middle East respiratory syndrome coronavirus

Key members of the ONCoV Genomics Coalition, Samira Mubareka and Andrew McArthur conducted a collaborative study analyzing and predicting the recombination potential of SARS-CoV-2 and the Middle East respiratory syndrome coronavirus.

September 9, 2020

    Contact    

 

© 2020 by Ontario Genomics